NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This best-selling Marketdata study is a comprehensive analysis of the fragmented but sizeable $57 billion U.S. clinical lab testing business. The industry was hurt by the recession but is poised for moderate growth to 2013, as the U.S. population ages and new tests are developed. Higher margin esoteric and anatomic pathology tests are pacing growth and the large chains have made a string of acquisitions in this space, to "buy" growth. International expansion could be the next growth frontier.
The study examines, in detail, recent industry trends and developments in the major test segments: PAP tests, workplace drug screening, and esoteric tests. An entire chapter is devoted to the high-growth $6.6 billion "esoteric" or reference test market—its size, growth, nature, profiles of all key competitors, with revenue rankings.
Complete analysis of independent commercial labs, hospital labs, and physician office labs-how they differ and compete, discussion of major industry trends and demand factors, extensive national/state operating ratios/latest Census and CLIA data. Analysis of industry receipts from 1980-2008 actual, 2009 performance and 2010 outlook, 2013 forecasts, lab staff salaries and vacancy rates, insurance industry testing, latest trade journal survey findings. Estimates and opinions of multiple brokerage firms. Competitor profiles for: Quest Diagnostics, Lab Corp. of America Holdings, Bio-Reference Labs, American Esoteric Labs, Ameripath, ARUP, Genzyme, Medtox Scientific, Clinical Pathology Labs, Mayo Medical Labs, Spectrum Lab Network, Sonora Quest Labs, and more. Contains reference directory of industry sources, list of NIDA-certified drug test labs. This study contains 113 tables and charts, and is also sold by chapters. It is available via several commercial databases as well.
To order this report:: The U.S. Medical Laboratories Industry - 10th Edition
Copyright©2010 PR Newswire.
All rights reserved